Complete remission · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes number with complete remission: complete remission in all patients compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Adverse events: bronchospasm/treatment discontinued · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: bronchospasm/treatment discontinued compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Adverse events: hypotension · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: hypotension compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Adverse effects of antibiotics (skin rash) · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: skin rash compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Adverse events: mild dyspnoea · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: mild dyspnoea compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Observed number of pregnancies (all women) · women seeking emergency contraception
Mid‐dose mifepristone (25 mg‐50 mg) leads to lower observed number of pregnancies (all women) compared with low‐dose mifepristone (< 25 mg) (high certainty).
1 finding from 1 review
Side effects · women seeking emergency contraception
Mid‐dose mifepristone (25 mg‐50 mg) probably leads to higher any side effect compared with low‐dose mifepristone (< 25 mg) (moderate certainty).
1 finding from 1 review
Nausea · women seeking emergency contraception
Mid‐dose mifepristone (25 mg‐50 mg) showed no clear difference in specific side effects ‐ nausea compared with low‐dose mifepristone (< 25 mg) (moderate certainty).
1 finding from 1 review
Vomiting · women seeking emergency contraception
Mid‐dose mifepristone (25 mg‐50 mg) showed no clear difference in specific side effects ‐ vomiting compared with low‐dose mifepristone (< 25 mg) (moderate certainty).
1 finding from 1 review
Specific side effects ‐ spotting/bleeding after treatment · women seeking emergency contraception
Mid‐dose mifepristone (25 mg‐50 mg) leads to higher specific side effects ‐ spotting/bleeding after treatment compared with low‐dose mifepristone (< 25 mg) (high certainty).
1 finding from 1 review
Menses ‐ early · women seeking emergency contraception
Mid‐dose mifepristone (25 mg‐50 mg) showed no clear difference in menses ‐ early compared with low‐dose mifepristone (< 25 mg) (low certainty).
1 finding from 1 review
Menses ‐ delay · women seeking emergency contraception
Mid‐dose mifepristone (25 mg‐50 mg) probably leads to higher menses ‐ delay compared with low‐dose mifepristone (< 25 mg) (moderate certainty).
1 finding from 1 review
Disease control (time when steroid could be discontinued) · bullous pemphigoid
1 finding from 1 review
Mortality at 1 year · bullous pemphigoid
It is very uncertain whether methylprednisolone plus azathioprine changes mortality at 1 year compared with methylprednisolone plus dapsone (very low certainty).
1 finding from 1 review
Quality of life ‐ not measured · bullous pemphigoid
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events at 1 year · bullous pemphigoid
1 finding from 1 review
Adverse events associated with treatment · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
Oral methotrexate and oral prednisone showed no clear difference in primary outcome: Adverse effects compared with placebo and oral prednisone (low certainty).
1 finding from 1 review
Secondary outcome: Improvement of disease activity (reduction in lesion size) · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
1 finding from 1 review
Secondary outcome: Improvement of disease damage ‐ not measured · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
1 finding from 1 review
Side effects · People with erosive oral lichen planus
1 finding from 1 review
Table 3 (Side-effects). Malhotra 2008: betamethasone oral mini-pulse - transient oedema over the face (7), oedema over hands and feet (4), epigastric discomfort (7), weakness/fatigue (5), loose stools (1), headache…
1 study · 22 participants
GRADE not reported